Emerging options in the treatment of dyslipidemias: a bright future? (Q37842462)

24 August 2017

1 reference

title

Emerging options in the treatment of dyslipidemias: a bright future? (English)

1 reference

24 August 2017

1 reference

Evangelos N Liberopoulos

series ordinal

2

1 reference

24 August 2017

Dimitri P Mikhailidis

series ordinal

3

object named as

Dimitri P Mikhailidis

1 reference

24 August 2017

Matilda Florentin

1

1 reference

24 August 2017

Moses S Elisaf

series ordinal

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 February 2011

1 reference

Expert Opinion on Emerging Drugs

24 August 2017

1 reference

24 August 2017

16

1 reference

24 August 2017

247-270

1 reference

24 August 2017

2

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Simvastatin with or without ezetimibe in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Monogenic hypercholesterolemia: new insights in pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Surgical management of dyslipidemia: clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Long-term effects of LDL apheresis in patients with severe hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Recommendations for the use of LDL apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

High-density lipoproteins: epidemiologic profile and risks of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Epidemiology of triglycerides: a view from Framingham

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: a 10-year prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effects of monounsaturated enriched sunflower oil on CHD risk factors including LDL size and copper-induced LDL oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

An overview of the extra-lipid effects of rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Statin pleiotropy against renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Do statins have an antiarrhythmic activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Statins: another class of antihypertensive agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Statin-associated adverse effects beyond muscle and liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Ezetimibe-associated adverse effects: what the clinician needs to know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Bile acid regulation of gene expression: roles of nuclear hormone receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Preferential Utilization of Free Cholesterol From High-Density Lipoproteins for Biliary Cholesterol Secretion in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Peroxisome proliferator-activated receptor translational research and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Regulation of apo A-I gene expression by fibrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effects of fibrates on serum metabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Safety considerations with fibrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Risk of adverse events with fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Fibrate-associated adverse effects beyond muscle and liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Fibrates and microvascular complications in diabetes--insight from the FIELD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Combination therapy with statins and omega-3 fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Omega-3 polyunsaturated fatty acids and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Cardiovascular effects of marine omega-3 fatty acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Extended-release niacin for modifying the lipoprotein profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Niacin and cholesterol: role in cardiovascular disease (review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

High Density Lipoprotein Metabolism in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Molecular identification of nicotinic acid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Langerhans cells release prostaglandin D2 in response to nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

The mechanism and mitigation of niacin-induced flushing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

The safety of niacin in the US Food and Drug Administration adverse event reporting database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effects of niacin on glucose control in patients with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Safety considerations with niacin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Other therapies for reducing low-density lipoprotein cholesterol: medications in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Increasing apoA-I production as a target for CHD risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Structure and function of HDL mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Future challenges for microsomal transport protein inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Apolipoprotein B, a paradigm for proteins regulated by intracellular degradation, does not undergo intracellular degradation in CaCo2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Therapeutic potential of RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

RNAi-mediated gene silencing in non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Multiple actions of high-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Antiatherogenic small, dense HDL--guardian angel of the arterial wall?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Spotlight on HDL-raising therapies: insights from the torcetrapib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

The continuing importance of bile acids in liver and intestinal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 alpha-hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Effect of ACAT inhibition on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Squalene synthase inhibition: a novel target for the management of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Cholesterol modification of hedgehog signaling proteins in animal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Disorders of cholesterol biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

Fatty Acid Regulation of Gene Transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

21 January 2018

GISSI-Prevenzione trial

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.554395

10.1517/14728214.2011.554395

21 January 2018

Identifiers

DOI

1 reference

release_bwfufsj3nfe33kxhutvjvmk7qu

24 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bwfufsj3nfe33kxhutvjvmk7qu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference